CTLA4 and cancer: Along with the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathway [23], this pathway is a crucial target for novel cancer therapeutics, including the monoclonal antibodies (mAbs), peptides, and patented small molecules.